Literature DB >> 19689976

XF-73, a novel antistaphylococcal membrane-active agent with rapid bactericidal activity.

Nicola Ooi1, Keith Miller, Joanne Hobbs, William Rhys-Williams, William Love, Ian Chopra.   

Abstract

OBJECTIVES: XF-73 is a novel porphyrin antibacterial agent previously reported to inhibit a range of gram-positive bacterial species, including Staphylococcus aureus. Its mode of action is unknown. Using S. aureus as a model organism we sought to examine the basis of its antibacterial activity.
METHODS: The effects of XF-73 on the growth and survival of S. aureus SH1000 were investigated by viable count and culture absorbance techniques. Inhibition of macromolecular synthesis and disruption of membrane integrity after exposure to XF-73 were examined by radiolabelling experiments, the BacLight fluorescent dye assay and measurement of K(+) and ATP leakage from the cell. The effect of XF-73 on a staphylococcal coupled transcription-translation system was also investigated.
RESULTS: XF-73 was rapidly bactericidal against S. aureus SH1000 and demonstrated more rapid killing kinetics than all other comparator agents when tested at an equivalent multiple (4x) of the MIC. Exposure of S. aureus to XF-73 for 10 min completely inhibited DNA, RNA and protein synthesis. XF-73 had no effect on transcription and translation in vitro. Cells exposed to XF-73 gave a positive response in the BacLight assay, which detects membrane damage. The drug also caused substantial loss of K(+) and ATP from the cell, but did not promote bacterial lysis.
CONCLUSIONS: XF-73 exhibited rapid membrane-perturbing activity, which is likely to be responsible for inhibition of macromolecular synthesis and the death of staphylococci exposed to the drug.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19689976     DOI: 10.1093/jac/dkp299

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  26 in total

Review 1.  Antibiotics in the clinical pipeline at the end of 2015.

Authors:  Mark S Butler; Mark At Blaskovich; Matthew A Cooper
Journal:  J Antibiot (Tokyo)       Date:  2016-06-29       Impact factor: 2.649

2.  Further characterization of Bacillus subtilis antibiotic biosensors and their use for antibacterial mode-of-action studies.

Authors:  Katherine R Mariner; Nicola Ooi; Deborah Roebuck; Alex J O'Neill; Ian Chopra
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

3.  Neutral metallated and meso-substituted porphyrins as antimicrobial agents against gram-positive pathogens.

Authors:  W N Burda; K B Fields; J B Gill; R Burt; M Shepherd; X P Zhang; L N Shaw
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-06-12       Impact factor: 3.267

4.  A two-part phase 1 study to establish and compare the safety and local tolerability of two nasal formulations of XF-73 for decolonisation of Staphylococcus aureus: A previously investigated 0.5mg/g viscosified gel formulation versus a modified formulation.

Authors:  George A Yendewa; J McLeod Griffiss; Michael R Jacobs; Scott A Fulton; Mary Ann O'Riordan; Wesley A Gray; Howard M Proskin; Peter Winkle; Robert A Salata
Journal:  J Glob Antimicrob Resist       Date:  2019-10-07       Impact factor: 4.035

5.  Nonthermal dielectric-barrier discharge plasma-induced inactivation involves oxidative DNA damage and membrane lipid peroxidation in Escherichia coli.

Authors:  Suresh G Joshi; Moogega Cooper; Adam Yost; Michelle Paff; Utku K Ercan; Gregory Fridman; Gary Friedman; Alexander Fridman; Ari D Brooks
Journal:  Antimicrob Agents Chemother       Date:  2011-01-03       Impact factor: 5.191

Review 6.  Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections.

Authors:  Julian G Hurdle; Alex J O'Neill; Ian Chopra; Richard E Lee
Journal:  Nat Rev Microbiol       Date:  2011-01       Impact factor: 60.633

Review 7.  Advances in MRSA drug discovery: where are we and where do we need to be?

Authors:  Michio Kurosu; Shajila Siricilla; Katsuhiko Mitachi
Journal:  Expert Opin Drug Discov       Date:  2013-07-06       Impact factor: 6.098

Review 8.  Strategies against methicillin-resistant Staphylococcus aureus persisters.

Authors:  Wooseong Kim; Gabriel L Hendricks; Katerina Tori; Beth B Fuchs; Eleftherios Mylonakis
Journal:  Future Med Chem       Date:  2018-03-23       Impact factor: 3.808

9.  Nonconventional Therapeutics against Staphylococcus aureus.

Authors:  Caroline M Grunenwald; Monique R Bennett; Eric P Skaar
Journal:  Microbiol Spectr       Date:  2018-11

10.  Investigation of the potential for mutational resistance to XF-73, retapamulin, mupirocin, fusidic acid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus isolates during a 55-passage study.

Authors:  David J Farrell; Marion Robbins; William Rhys-Williams; William G Love
Journal:  Antimicrob Agents Chemother       Date:  2010-12-13       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.